StockNews.com upgraded shares of Iradimed (NASDAQ:IRMD - Free Report) from a buy rating to a strong-buy rating in a research note released on Tuesday.
Iradimed Trading Down 1.8 %
Shares of IRMD stock traded down $1.10 during mid-day trading on Tuesday, reaching $59.21. The stock had a trading volume of 30,727 shares, compared to its average volume of 33,916. Iradimed has a 1-year low of $40.18 and a 1-year high of $61.24. The firm has a market cap of $750.19 million, a price-to-earnings ratio of 40.56 and a beta of 0.81. The business's fifty day moving average is $56.02 and its 200-day moving average is $51.23.
Insider Buying and Selling at Iradimed
In other news, CFO John Glenn sold 2,500 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares of the company's stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 37.10% of the company's stock.
Institutional Trading of Iradimed
Several hedge funds and other institutional investors have recently bought and sold shares of IRMD. R Squared Ltd purchased a new stake in Iradimed in the 4th quarter worth approximately $30,000. Huntington National Bank lifted its stake in shares of Iradimed by 51.3% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider's stock valued at $75,000 after purchasing an additional 504 shares during the period. Gladius Capital Management LP grew its position in Iradimed by 126.6% during the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider's stock valued at $87,000 after buying an additional 965 shares during the period. Quantbot Technologies LP grew its position in Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider's stock valued at $117,000 after buying an additional 1,052 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in Iradimed in the third quarter valued at $126,000. 92.34% of the stock is owned by institutional investors and hedge funds.
Iradimed Company Profile
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Further Reading
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
